Brief: Algernon Pharmaceuticals Announces Topline Data From Its Phase 2B/3 Covid-19 Trial Of Ifenprodil

Grey Matters Health

31/03/2021 14:03

March 31 (Reuters) - Algernon Pharmaceuticals Inc  AGN.CD :
    * ALGERNON -  AT DAY 15 OF COVID-19 TRIAL THERE WAS 0%
MORTALITY
IN 20 MG DOSE IFENPRODIL TREATMENT ARM VERSUS 3.3% MORTALITY
RATE IN UNTREATED CONTROL ARM
    * ALGERNON PHARMACEUTICALS INC - BASED ON INITIAL DATA
REVIEW, NO
SIGNIFICANT CHANGES WERE OBSERVED IN 40 MG DOSE GROUP
    * ALGERNON - OF PATIENTS WITH LOW BLOOD OXYGEN LEVEL, 100%
IN 20
MG DOSE TREATMENT ARM RETURNED TO NORMAL LEVELS OF O2 AT DAY 4
VERSUS DAY 9 IN UNTREATED ARM

Source text for Eikon:  ID:nGNX2b1qj0 
Further company coverage:  AGN.CD 

 ((Reuters.Briefs@thomsonreuters.com;))